NEXT Financial Group Inc Has $510,000 Stake in West Pharmaceutical Services Inc. (NYSE:WST)

NEXT Financial Group Inc decreased its position in West Pharmaceutical Services Inc. (NYSE:WST) by 10.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,079 shares of the medical instruments supplier’s stock after selling 494 shares during the period. NEXT Financial Group Inc’s holdings in West Pharmaceutical Services were worth $510,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Oregon Public Employees Retirement Fund raised its holdings in West Pharmaceutical Services by 1.4% during the second quarter. Oregon Public Employees Retirement Fund now owns 29,970 shares of the medical instruments supplier’s stock worth $3,751,000 after buying an additional 424 shares during the last quarter. First Hawaiian Bank raised its holdings in shares of West Pharmaceutical Services by 29.2% in the 2nd quarter. First Hawaiian Bank now owns 2,239 shares of the medical instruments supplier’s stock worth $280,000 after acquiring an additional 506 shares during the last quarter. First Citizens Bank & Trust Co. acquired a new stake in shares of West Pharmaceutical Services in the 2nd quarter worth about $627,000. Zions Bancorporation N.A. raised its holdings in shares of West Pharmaceutical Services by 3.0% in the 2nd quarter. Zions Bancorporation N.A. now owns 5,242 shares of the medical instruments supplier’s stock worth $656,000 after acquiring an additional 155 shares during the last quarter. Finally, FMR LLC raised its holdings in shares of West Pharmaceutical Services by 41.3% in the 1st quarter. FMR LLC now owns 794 shares of the medical instruments supplier’s stock worth $88,000 after acquiring an additional 232 shares during the last quarter. Institutional investors and hedge funds own 91.62% of the company’s stock.

Shares of WST stock traded down $1.72 on Friday, hitting $135.56. The stock had a trading volume of 322,850 shares, compared to its average volume of 339,073. The company’s 50 day moving average is $125.39. The company has a market cap of $10.12 billion, a PE ratio of 48.24, a price-to-earnings-growth ratio of 3.91 and a beta of 1.30. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.13 and a current ratio of 3.02. West Pharmaceutical Services Inc. has a 12-month low of $91.75 and a 12-month high of $139.59.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, July 25th. The medical instruments supplier reported $0.89 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.72 by $0.17. The company had revenue of $469.70 million during the quarter, compared to the consensus estimate of $459.90 million. West Pharmaceutical Services had a net margin of 12.94% and a return on equity of 16.93%. The firm’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.70 earnings per share. As a group, equities analysts forecast that West Pharmaceutical Services Inc. will post 3.07 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 6th. Shareholders of record on Wednesday, October 23rd will be paid a $0.15 dividend. The ex-dividend date is Tuesday, October 22nd. This represents a $0.60 annualized dividend and a yield of 0.44%. West Pharmaceutical Services’s dividend payout ratio (DPR) is 21.35%.

WST has been the subject of several analyst reports. William Blair initiated coverage on West Pharmaceutical Services in a research note on Tuesday, April 23rd. They issued an “outperform” rating and a $112.16 price objective for the company. Jefferies Financial Group downgraded West Pharmaceutical Services from a “buy” rating to a “hold” rating and set a $122.00 price objective for the company. in a research note on Wednesday, May 1st. Bank of America raised West Pharmaceutical Services from an “underperform” rating to a “neutral” rating in a research note on Friday, July 26th. Finally, Zacks Investment Research raised West Pharmaceutical Services from a “sell” rating to a “hold” rating in a research report on Friday, May 3rd. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $123.05.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

Featured Article: Overbought

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.